Abstract

The Ser/Thr kinase MAP4K4, like other GCKIV kinases, has N-terminal kinase and C-terminal citron homology (CNH) domains. MAP4K4 can activate c-Jun N-terminal kinases (JNKs), and studies in the heart suggest it links oxidative stress to JNKs and heart failure. In other systems, MAP4K4 is regulated in striatin-interacting phosphatase and kinase (STRIPAK) complexes, in which one of three striatins tethers PP2A adjacent to a kinase to keep it dephosphorylated and inactive. Our aim was to understand how MAP4K4 is regulated in cardiomyocytes. The rat MAP4K4 gene was not properly defined. We identified the first coding exon of the rat gene using 5′-RACE, we cloned the full-length sequence and confirmed alternative-splicing of MAP4K4 in rat cardiomyocytes. We identified an additional α-helix C-terminal to the kinase domain important for kinase activity. In further studies, FLAG-MAP4K4 was expressed in HEK293 cells or cardiomyocytes. The Ser/Thr protein phosphatase inhibitor calyculin A (CalA) induced MAP4K4 hyperphosphorylation, with phosphorylation of the activation loop and extensive phosphorylation of the linker between the kinase and CNH domains. This required kinase activity. MAP4K4 associated with myosin in untreated cardiomyocytes, and this was lost with CalA-treatment. FLAG-MAP4K4 associated with all three striatins in cardiomyocytes, indicative of regulation within STRIPAK complexes and consistent with activation by CalA. Computational analysis suggested the interaction was direct and mediated via coiled-coil domains. Surprisingly, FLAG-MAP4K4 inhibited JNK activation by H2O2 in cardiomyocytes and increased myofibrillar organisation. Our data identify MAP4K4 as a STRIPAK-regulated kinase in cardiomyocytes, and suggest it regulates the cytoskeleton rather than activates JNKs.

Highlights

  • MAP4K4 was first cloned from mouse cells in 1997 as NIK (Nck-interacting kinase) [1] and later from human cells as HGK (HPK/Germinal Center Kinase (GCK)-like kinase) [2]

  • MAP4K4 is emerging as a key regulatory kinase involved in the development of major diseases in society including cardiovascular disease and cancer [4,5]

  • With respect to its regulation, despite reports suggesting MAP4K4 acts as an intermediate signalling component [2,7], it seems much more probable that it is regulated in the context of striatin-interacting phosphatase and kinase (STRIPAK) complexes where a striatin tethers the kinase in the vicinity of phosphatase 2A (PP2A) which maintains it in a dephosphorylated and inactive state [13,14,15]

Read more

Summary

Introduction

MAP4K4 was first cloned from mouse cells in 1997 as NIK (Nck-interacting kinase) [1] and later from human cells as HGK (HPK/GCK-like kinase) [2]. MAP4K4 is a STE20 Ser/Thr protein kinase, belonging to the Germinal Center Kinase (GCK) family, with a conserved N-terminal catalytic domain and C-terminal regulatory domain. MAP4K4, TNIK (MAP4K7) and MINK (MAP4K6) constitute the GCKIV subfamily, having a conserved citron homology (CNH) domain towards the C terminus and a large unstructured region between the kinase and the CNH [3]. MAP4K4 is highly expressed in the heart, with potentially the highest mRNA levels across all normal adult tissues studied [1,2]. MAP4K4 activity is linked to cardiovascular disease and heart failure, but it is associated with other major diseases including cancer [4,5]. There is, considerable focus on identifying selective small molecule inhibitors for the kinase

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.